Press release
Primary Biliary Cholangitis Pipeline Drugs Report 2025: Transformative Research, Competitive Landscape, and Future Treatment Prospects
Curious about the latest updates in the Primary Biliary Cholangitis Pipeline? Click here to explore the therapies and trials making headlines @ Primary Biliary Cholangitis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Primary Biliary Cholangitis Pipeline Report
* On 12 September 2025, Gilead Sciences conducted a study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
* On 10 September 2025, Kowa Research Institute Inc . announced a Phase 2 Multicenter 12-week Study With a 52-week Extension to Evaluate the Efficacy and Safety of Two Doses of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid and/or Obeticholic Acid Treatment.
* DelveInsight's Primary Biliary Cholangitis Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Primary Biliary Cholangitis treatment.
* The leading Primary Biliary Cholangitis Companies such as Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline and others.
* Promising Primary Biliary Cholangitis Therapies such as Saroglitazar Magnesium 1 mg, Seladelpar, ASC42 5 mg, Elafibranor, Obeticholic Acid Tablets, Bezafibrate 100 mg, Obeticholic Acid 5 mg and others.
Want to know which companies are leading innovation in Primary Biliary Cholangitis? Dive into the full pipeline insights @ Primary Biliary Cholangitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Primary Biliary Cholangitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Primary Biliary Cholangitis Pipeline Report also highlights the unmet needs with respect to the Primary Biliary Cholangitis.
Primary Biliary Cholangitis Overview
Primary Biliary Cholangitis (PBC) is a chronic, progressive autoimmune disease that primarily affects the bile ducts in the liver. It leads to inflammation and gradual destruction of the small bile ducts, causing bile to accumulate in the liver (cholestasis). Over time, this can result in liver damage, fibrosis, and eventually cirrhosis. Although the exact cause of PBC remains unclear, it predominantly affects middle-aged women and is considered an autoimmune disorder. Genetic and environmental factors, such as infections or toxic exposures, may contribute to its onset.
Primary Biliary Cholangitis (PBC) Emerging Drugs
* Saroglitazar Magnesium: Zydus Therapeutics
Saroglitazar (LIPAGLYN) contains two main classes of PPAR agonists, which include PPAR (alpha) and PPAR (gamma). The drug has lipid and glucose-lowering effects in a single molecule; it lowers high blood triglycerides and blood sugar and improves insulin resistance. The drug is available in tablet form of 4 mg dose for oral administration. Saroglitazar is indicated for treating diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated a reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, and non-HDL cholesterol and an increase in HDL cholesterol, a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). The US FDA has granted ODD and FTD to saroglitazar Mg for PBC. It is currently being investigated in Phase III stage of clinical development for the treatment of Primary Biliary Cholangitis.
* Setanaxib: Calliditas Therapeutics
Setanaxib (GKT831), a NOX1 and NOX4 inhibitor, has shown evidence of anti-fibrotic activity in a Phase II clinical trial in primary biliary cholangitis (PBC, an orphan liver disease). Based on its Phase II results, a phase II/III trial with Setanaxib in PBC was initiated. Setanaxib is also being evaluated in an investigator-initiated Phase II clinical trial in Type 1 Diabetes and Kidney Disease (DKD) as well as being studied in an investigator led Phase II clinical trial in idiopathic pulmonary fibrosis (IPF), a chronic lung disease that results in fibrosis of the lungs. Currently the drug is in Phase II stage of its development for the treatment of Primary biliary cholangitis.
* HPG-1860: Hepagene
HPG-1860 is under development for the treatment of non-alcoholic steatohepatitis (NASH), Primary Biliary Cholangitis. It is administered by oral route. The drug candidate is an avermectin derivative and acts by targeting farnesoid X activated receptor. The drug is currently in phase I stage of development for the treatment of PBC. The drug is currently in Phase I stage of its clinical development for the study of Primary Biliary Cholangitis (PBC).
If you're tracking ongoing Primary Biliary Cholangitis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Primary Biliary Cholangitis Treatment Drugs [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Primary Biliary Cholangitis Companies
Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline and others.
Primary Biliary Cholangitis (PBC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Primary Biliary Cholangitis Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
From emerging drug candidates to competitive intelligence, the Primary Biliary Cholangitis Pipeline Report covers it all - check it out now @ Primary Biliary Cholangitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Primary Biliary Cholangitis Pipeline Report
* Coverage- Global
* Primary Biliary Cholangitis Companies- Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline and others.
* Primary Biliary Cholangitis Therapies- Saroglitazar Magnesium 1 mg, Seladelpar, ASC42 5 mg, Elafibranor, Obeticholic Acid Tablets, Bezafibrate 100 mg, Obeticholic Acid 5 mg and others.
* Primary Biliary Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Primary Biliary Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Primary Biliary Cholangitis treatment landscape in this detailed analysis @ Primary Biliary Cholangitis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Primary Biliary Cholangitis (PBC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Primary Biliary Cholangitis (PBC)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Saroglitazar Magnesium: Zydus Therapeutics
* Mid Stage Products (Phase II)
* Setanaxib: Calliditas Therapeutics
* Early Stage Products (Phase I)
* HPG-1860: Hepagene
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Primary Biliary Cholangitis (PBC) Key Companies
* Primary Biliary Cholangitis (PBC) Key Products
* Primary Biliary Cholangitis (PBC)- Unmet Needs
* Primary Biliary Cholangitis (PBC)- Market Drivers and Barriers
* Primary Biliary Cholangitis (PBC)- Future Perspectives and Conclusion
* Primary Biliary Cholangitis (PBC) Analyst Views
* Primary Biliary Cholangitis (PBC) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-biliary-cholangitis-pipeline-drugs-report-2025-transformative-research-competitive-landscape-and-future-treatment-prospects]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/primary-biliary-cholangitis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Pipeline Drugs Report 2025: Transformative Research, Competitive Landscape, and Future Treatment Prospects here
News-ID: 4187174 • Views: …
More Releases from ABNewswire
Biopreservation Market to Grow at a CAGR of ~7.5% Driven by Rising Demand in Cel …
The biopreservation market is growing rapidly, driven by increased adoption of cell and gene therapies, rising organ transplantation demand, and the need for advanced preservation solutions for biologics and vaccines. With the rise of chronic diseases and advances in regenerative medicine, the demand for reliable technologies like cryopreservation, hypothermic storage, and next-generation perfusion systems is expanding worldwide.
Innovations such as DMSO-free cryopreservation media, advanced hypothermic and normothermic organ perfusion systems, ambient…
Blood Gas and Electrolyte Analyzers Market Poised to Register a CAGR of ~5.65% b …
The blood gas and electrolyte analyzers market is witnessing strong momentum, fueled by the rising global burden of chronic diseases, growing demand for critical care monitoring, and the increasing adoption of point-of-care testing (POCT) in emergency and intensive care settings. These analyzers play a crucial role in measuring parameters such as pH, oxygen, carbon dioxide, electrolytes, and metabolites, enabling timely diagnosis and effective management of critically ill patients.
Technological advancements, including…
Fetal & Neonatal Care Equipment Market Poised to Register a CAGR of ~8.33% by 20 …
The fetal & neonatal care equipment market is experiencing sustained growth, driven by the rising global burden of preterm births, increasing neonatal intensive care unit (NICU) admissions, and advancements in life-saving technologies for newborns. Preterm and low-birth-weight infants remain highly vulnerable, requiring specialized monitoring, respiratory support, and thermal regulation, which is fueling demand for advanced neonatal care solutions worldwide.
Innovations such as non-invasive monitoring systems, advanced neonatal ventilators, smart incubators, phototherapy…
ER+/HER2- Breast Cancer Market Set for Significant CAGR, Driven by Recent FDA Ap …
The ER+/HER2- breast cancer market is projected to experience significant growth through 2034, driven by rising disease prevalence, advancements in targeted therapies, and an expanding pipeline of novel treatment options developed by key players including Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and others.
DelveInsight's "ER+/HER2- Breast Cancer - Market Insights, Epidemiology and Market Forecast - 2034 [https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
